AI Article Synopsis

  • Two cases of primary limited cutaneous perineal and genital extramammary Paget's disease (EMPD) were treated successfully with imiquimod 5% cream.
  • After 7.5 to 12 weeks of treatment, clinical and histologic healing was confirmed.
  • Imiquimod presents a less invasive and convenient option for managing EMPD, with minimal side effects compared to more traditional therapies.

Article Abstract

We present two cases of primary limited cutaneous perineal and genital extramammary Paget's disease (EMPD) that were successfully treated with imiquimod 5% cream. Clinical and histologic cure was confirmed after 7.5 to 12 weeks of monotherapy. Treatment-associated morbidity is minimal compared with more invasive therapies, and self-application by the patient improves convenience and appeal. Imiquimod may offer a minimally invasive and promising therapeutic option for the treatment of limited cutaneous EMPD. The diagnosis and management of EMPD and the current literature regarding imiquimod therapy are reviewed.

Download full-text PDF

Source
http://dx.doi.org/10.1067/mjd.2002.126584DOI Listing

Publication Analysis

Top Keywords

limited cutaneous
12
primary limited
8
extramammary paget's
8
paget's disease
8
treatment primary
4
cutaneous extramammary
4
disease topical
4
imiquimod
4
topical imiquimod
4
imiquimod monotherapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!